NiKem Research and Hybrigenics Expand Research Service Agreement

NiKem Research Srl and Hybrigenics SA announced that they have expanded and extended a research service agreement already in place between the two companies. Under the terms of the agreement, NiKem will continue using its medicinal chemistry platform and expertise to optimize inhibitors of Ubiquitin Specific Proteases (USP) as new therapeutic agents against cancer. This family of proteases has been the focus of thorough target identification and validation studies by Hybrigenics in the field of Oncology.

BioPortfolio (http://www.bioportfolio.com/news/NiKem_Research_1.htm)